| CAS ID: | 1152311-62-0 |
| Molecular Formula: | C26H27F3N2O6 |
| Molecular Weight: | 520.5 g/mol |
| Monoisotopic Mass: | 520.1821 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | TEZACAFTOR | VX-661 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1 | See All |
| InChI Key: | MJUVRTYWUMPBTR-MRXNPFEDSA-N | |
| Smiles: | CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c4ccc5OC(F)(F)Oc5c4)c(F)cc2n1C[C@@H](O)CO | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 29099344 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT03227471 | Disease | Cystic fibrosis |
| Phase | Phase 1,Phase 2 | Status | Completed |
| First Received | July 24, 2017 | Last Verified | April 30, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 2
| ClinicalTrial ID | NCT02951195 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 1, 2016 | Last Verified | January 14, 2019 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 3
| ClinicalTrial ID | NCT03278314 | Disease | Cystic fibrosis |
| Phase | Status | - | |
| First Received | September 11, 2017 | Last Verified | November 2, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 4
| ClinicalTrial ID | NCT02951182 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 1, 2016 | Last Verified | August 15, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 5
| ClinicalTrial ID | NCT03029455 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | January 24, 2017 | Last Verified | September 5, 2017 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 6
| ClinicalTrial ID | NCT02953314 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 2, 2016 | Last Verified | October 5, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 7
| ClinicalTrial ID | NCT02730208 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | April 6, 2016 | Last Verified | August 24, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 8
| ClinicalTrial ID | NCT02565914 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Enrolling by invitation |
| First Received | October 1, 2015 | Last Verified | November 22, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 9
| ClinicalTrial ID | NCT02508207 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | July 24, 2015 | Last Verified | July 27, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 10
| ClinicalTrial ID | NCT01531673 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 13, 2012 | Last Verified | April 13, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 11
| ClinicalTrial ID | NCT02070744 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 25, 2014 | Last Verified | April 13, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 12
| ClinicalTrial ID | NCT02516410 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 5, 2015 | Last Verified | June 12, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 13
| ClinicalTrial ID | NCT02392234 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 18, 2015 | Last Verified | June 12, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 14
| ClinicalTrial ID | NCT02412111 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | April 8, 2015 | Last Verified | January 8, 2019 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 15
| ClinicalTrial ID | NCT03150719 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 12, 2017 | Last Verified | October 1, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 16
| ClinicalTrial ID | NCT02347657 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | January 27, 2015 | Last Verified | June 12, 2018 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
Trial Record 17
| ClinicalTrial ID | NCT02015507 | Disease | Cystic fibrosis |
| Phase | Phase 1 | Status | Completed |
| First Received | December 19, 2013 | Last Verified | March 26, 2014 |
| Sponsor | Vertex Pharmaceuticals Incorporated | ||
| PubChem: | 46199646 |
| ChEMBL: | CHEMBL3544914 |